Trial Profile
A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Alemtuzumab; Alemtuzumab; Bortezomib
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 09 May 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Actual end date (December 2010) added as reported by ClinicalTrials.gov.